Today: 3 June 2026
BP stock price slides as buybacks stop — debt cuts and new CEO take over the story
10 February 2026
2 mins read

BP stock price slides as buybacks stop — debt cuts and new CEO take over the story

London, Feb 10, 2026, 10:00 GMT — Regular session

  • BP sank roughly 5% after the oil giant hit the brakes on its quarterly share buyback.
  • Q4 underlying replacement cost profit landed at $1.54 billion, with net debt trimmed to roughly $22 billion, the company said.
  • Debt reduction is in focus, with traders eyeing asset sales—Castrol remains a key piece. The CEO handover set for April is also on their radar.

BP dropped 5.2% to 452.6 pence in London trading on Tuesday, after the oil giant put its quarterly share buyback program on hold—a signal to investors that balance sheet health is now in focus.

The pause on buybacks is notable—oil majors leaned hard on repurchases to reward shareholders as crude prices eased back. Fewer shares out there, thanks to buybacks, can push up earnings per share even as profit growth loses steam.

The timing comes just before an April leadership shakeup: a new chief executive is stepping in following months of strategic back-and-forth and heated arguments among investors about where BP should commit its capital. Traders are now left wondering how long the buyback pause will last, and what BP will want to see — oil prices, cash flow, asset sales — before the program is restarted.

BP is halting its $750 million quarterly share buyback, shifting surplus cash to pay down debt and fund oil and gas investments instead. The company is also booking about $4 billion in impairments tied to its renewables and biogas operations. “The move to pause the buyback is the right long-term call given the relatively weak balance sheet and emphasis on de-leveraging,” said RBC’s Biraj Borkhataria. For the fourth quarter, BP posted underlying replacement cost profit — its preferred adjusted earnings metric — of $1.54 billion. Net debt slipped to $22 billion after sitting at $26 billion the previous quarter. Reuters

That move is notable, with the sector still under pressure to protect shareholder payouts. Just last week, Equinor slashed its buyback. BP, meanwhile, faces stiffer comparisons on cash returns as Shell and Exxon haven’t budged from their buyback plans.

Oil didn’t deliver much of a lift. Brent crude edged up 0.4% to $69.33 a barrel as of 0916 GMT, with U.S. WTI managing a 0.3% increase to $64.58. Traders continued to factor in possible supply threats from U.S.–Iran tensions. “Unless there are concrete signs of supply disruptions, prices will likely start going lower,” noted PVM oil analyst Tamas Varga. Reuters

BP’s latest results show the board pulling the plug on share buybacks, choosing instead to funnel all “excess cash” into shoring up the balance sheet. The company dropped its old policy of keeping shareholder distributions at about 30%–40% of operating cash flow. For 2026, BP laid out capital spending at $13.0–$13.5 bln and projected $9–$10 bln in divestment and other proceeds, which includes roughly $6 bln from its planned Castrol deal. “We’ve made progress on our targets but there’s still plenty to do, and we know time is of the essence,” interim CEO Carol Howle said. TradingView

BP is dialing spending back toward hydrocarbons following an expensive foray into parts of the energy transition—a shift underscored for investors by recent write-downs. The company is touting its Bumerangue discovery in Brazil as a major upstream win, and says it’s aiming to begin appraisal drilling near the end of the year.

The risks here stand out. If oil prices tumble again, or refining margins slip, debt reduction could stall—and buybacks might stay on hold longer than investors hope. Disposal delays would add to the pressure. Big deals are still waiting on regulatory sign-off, too. If management misses those cash targets, expect the market to react fast.

Investor groups are turning up the heat on BP over its strategic direction. Follow This, an activist shareholder collective, has submitted a resolution before BP’s annual investor meeting in April, demanding the company provide greater transparency on how it plans to generate value if fossil-fuel demand drops, according to the Guardian.

Traders are looking ahead to April, when BP’s CEO transition and annual meeting will put the company’s approach to capital returns and its debt trajectory in the spotlight. The Castrol deal timeline will be in focus, too—investors want clarity on upcoming milestones and any news about the buyback restart. Further out, Bumerangue appraisal work in 2026 remains a key operational event to watch.

Latest articles

Archer Aviation trades under $7 as next test looms for air-taxi gamble

Archer Aviation trades under $7 as next test looms for air-taxi gamble

3 June 2026
Archer Aviation shares dipped below $7 premarket after closing at $6.74, as investors weigh heavy cash burn—$217.7 million Q1 net loss, $1.78 billion cash on hand—against hopes for first U.S. eVTOL flights this year; Cantor Fitzgerald cut its price target to $11 but kept an Overweight rating, while 46 disclosed risks and ongoing certification challenges cloud near-term outlook.
Broadcom’s $280 Billion AI Rally Hits Key Test

Broadcom’s $280 Billion AI Rally Hits Key Test

3 June 2026
Broadcom’s stock soared 14% in four days, adding $280 billion in value ahead of Wednesday’s earnings after Alphabet’s $80 billion equity raise spotlighted AI data-center suppliers; with options implying a 9% share move either way, investors await proof that surging AI demand is translating into real revenue growth.
J-Star Stock Moves Up After Texas Battery Update in Pre-Market

J-Star Stock Moves Up After Texas Battery Update in Pre-Market

3 June 2026
J-Star Holding Co. surged to $1.36 in premarket trading after new disclosures on its proposed $122.5 million Baytown, Texas solid-state battery plant, pushing shares above Nasdaq’s $1 minimum less than a week before a key shareholder vote on a reverse split aimed at regaining compliance.
Legend Biotech jumps 42% as traders look at results from small cancer study

Legend Biotech jumps 42% as traders look at results from small cancer study

3 June 2026
Legend Biotech shares soared 42% to $36.28 after early Phase 1 data showed all six higher-dose patients with relapsed or refractory B-cell non-Hodgkin lymphoma responded to its in vivo CAR-T therapy LB2501, with five complete responses; UBS raised its price target to $49, citing the therapy’s outlook, but the results are early and based on a small group with short follow-up.
T1 Energy Stock Falls Premarket After $32M KORE Battery Deal

T1 Energy Stock Falls Premarket After $32M KORE Battery Deal

3 June 2026
T1 Energy shares fell 1.3% premarket after announcing a $32 million KORE Power acquisition to expand into battery storage and AI data-center infrastructure, just a day after a 15.7% stock surge; Northland initiated coverage with an outperform rating and $16 target, but flagged deal execution and funding as key risks.
ICG plc stock slips in London after Asia-Pacific strategy hire lands
Previous Story

ICG plc stock slips in London after Asia-Pacific strategy hire lands

monday.com stock price: MNDY holds near $78 after guidance reset, 2027 targets shelved
Next Story

monday.com stock price: MNDY holds near $78 after guidance reset, 2027 targets shelved

Go toTop